NeoTract Receives Phoenix 2018 Emerging Growth Company Award for Outstanding Industry Achievement

The Emerging Growth Company award is presented to an organization that has undergone a strategically significant merger, a highly successful IPO, dramatic growth in sales, or the creation of a major new product or service. Last year, NeoTract was acquired by Teleflex Incorporated in a transaction valued at up to $1.1 billion.

“We are thrilled to be recognized with the Emerging Growth Award by the respected Phoenix conference organizers and our medtech community,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “I am pleased to share this award with every member of the NeoTract team. Although we are proud of our achievement as a business, we are even prouder that we’re succeeding in our mission to improve the lives of men around the world with benign prostatic hyperplasia (BPH).”

NeoTract’s FDA-cleared UroLift^® System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.

The Phoenix Awards recognize outstanding achievements in the medical device and diagnostic industry to individuals and companies selected by industry CEOs. NeoTract received the Phoenix Most Promising New Product Award in 2016.

About Wilson Sonsini Goodrich & Rosati

For more than 50 years, Wilson Sonsini Goodrich & Rosati has offered a broad range of services and legal disciplines focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leader in the fields of corporate governance and finance, mergers and acquisitions, private equity, securities litigation, employment law, intellectual property, and antitrust, among many other areas of law. With deep roots in Silicon Valley, Wilson Sonsini Goodrich & Rosati has offices in Austin; Beijing; Boston; Brussels; Hong Kong; London; Los Angeles; New York; Palo Alto; San Diego; San Francisco; Seattle; Shanghai; Washington, D.C.; and Wilmington, DE. For more information, visit www.wsgr.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

MA00323-01 Rev A

View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005041/en/